Is the metabolic cost of walking higher in people with diabetes? by Petrovic, M et al.
Is the metabolic cost of walking higher in people with diabetes? 
 
Petrovic M1, Deschamps K3, Verschueren SM3, Bowling FL2, Maganaris CN4, Boulton AJM2 
& Reeves ND1. 
 
1School of Healthcare Science, Faculty of Science & Engineering, Manchester Metropolitan 
University, UK, 2Faculty of Medical & Human Sciences, University of Manchester, UK, 
3Department of Rehabilitation Sciences, Katholieke Universiteit Leuven, Belgium, 4School of 
Sport and Exercise Sciences, Liverpool John Moores University, UK 
 
Running title: Cost of walking and joint work in diabetic neuropathy 
 
 
Corresponding author: 
 
Milos Petrovic 
School of Healthcare Science 
Faculty of Science & Engineering 
Manchester Metropolitan University 
John Dalton Building 
Manchester M1 5GD  
UK 
m.petrovic@mmu.ac.uk 
Tel: +441612475573 
 
2 
 
ABSTRACT 
People with diabetes walk slower and display biomechanical gait alterations compared to 
controls, but it remains unknown whether the metabolic cost of walking (CoW) is elevated. 
The aim of this study was to investigate the CoW and the lower limb concentric joint work as a 
major determinant of the CoW, in patients with diabetes and diabetic peripheral neuropathy 
(DPN). 31 non-diabetic controls (Ctrl); 22 diabetic patients without peripheral neuropathy 
(DM) and 14 patients with moderate/severe DPN, underwent gait analysis using a motion 
analysis system and force plates and treadmill walking using gas analyser to measure oxygen 
uptake. The CoW was significantly higher particularly in the DPN group compared to controls 
and also in the DM group (at selected speeds only) compared to controls, across a range of 
matched walking speeds. Despite the higher CoW in patients with diabetes, concentric lower 
limb joint work was significantly lower in DM and DPN groups compared to controls. The 
higher CoW is likely due to energetic inefficiencies associated with diabetes and DPN 
reflecting physiological and biomechanical characteristics. The lower concentric joint work in 
patients with diabetes might be a consequence of kinematic gait alterations and may represent a 
natural strategy aimed at minimizing the CoW. 
 
Keywords: walking efficiency, diabetic neuropathy, joint work, oxygen consumption, lower 
limb biomechanics. 
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INTRODUCTION 
Diabetes mellitus (DM) is a disease with a global reach, the prevalence of which is increasing 
at an alarming rate, with type 2 diabetes being particularly common among older adults. The 
prevalence of diabetes in most developed countries ranges between 2.1% (Iceland) and 10.5% 
Brazil (70, 82, 13). The world health organisation estimates that by 2025 as many as 200–300 
million people worldwide will have developed type 2 diabetes (69). 
Diabetic peripheral neuropathy (DPN) is one of the most common complications associated 
with diabetes occurring in 30–50% of patients and causing dysfunction of peripheral nerves 
(17, 22). Diabetic neuropathy affects sensory, motor and autonomic components of the nervous 
system. In terms of complications arising from diabetic neuropathy and impacting upon gait, a 
loss of sensory perception and impaired muscle function are major factors.  
Diabetes patients have consistently been shown to display a slower self-selected walking speed, 
and take shorter strides compared to age-matched controls (19, 46, 28). Diabetic patients also 
generate lower knee and ankle joint moments compared to controls during walking (56, 52, 
14). It could be suggested that diabetic patients walk more slowly at least in part to keep the 
joint moment demands of gait lower, which may therefore explain their lower walking speed. 
However, lower joint moments during gait in diabetic patients have also been shown to be 
independent of walking speed (14).  
The cost of walking (CoW) is another important factor that could contribute towards dictating a 
slower self-selected walking speed in diabetes patients. As walking speed increases, joint 
moments and work are expected to increase (24, 79), increasing the CoW. The slower self-
selected speed may therefore reflect the most efficient strategy for diabetes patients as 
previously shown in other populations (53, 6, 49, 84).  
The CoW is known to be higher in healthy elderly people compared to young adults, which 
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likely reflects energetic inefficiencies in older people (53). Despite previous studies describing 
gait alterations in people with diabetes, the CoW and its relation to walking speed remains 
unknown in this clinical population. Lower limb concentric joint work is closely related to the 
CoW, with higher joint work being linked to a higher CoW (24, 79). Knee and ankle concentric 
joint work has recently been shown to be lower in people with diabetes during walking at a 
self-selected speed compared to controls (14), which might suggest a lower CoW as a result. 
However, there are also a number of energetic inefficiencies present in patients with diabetes 
that might increase the CoW for any given speed. For example, the effects of non-enzymatic 
glycation has been shown to stiffen tendons in animal models of diabetes (30, 58, 61, 62, 63). 
A stiffer Achilles tendon may reduce the amount of elastic energy stored in the tendon during 
walking (based upon the assumption of lower forces and therefore smaller elongations resulting 
from the lower joint moments developed in diabetic patients compared to controls). Reduced 
elastic energy storage in the Achilles tendon would increase the amount of energy required 
from ankle muscles, thereby increasing the CoW. Other factors that could contribute to 
energetic inefficiencies during walking in diabetic patients include altered leverage around the 
foot due to diabetic foot deformities and increased antagonist muscle co-activation (80, 19, 33).  
The aim of this study was therefore to investigate the CoW (and the lower limb joint work as a 
major determinant of the CoW) in patients with diabetes and diabetic neuropathy compared to 
controls at a range of matched walking speeds. We hypothesised that due to the above-
mentioned inefficiencies in diabetes patients, they would display a higher CoW when walking 
at the same speed compared to controls and that this would be more marked in diabetes patients 
with DPN compared to those without. 
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MATERIALS AND METHODS 
Participants 
After receiving ethical approval from all relevant bodies, a total of sixty seven participants 
gave written informed consent to participate in this study. All procedures in this study 
complied with the declaration of Helsinki. All participants were aged over 40 years and were 
allocated into one of three groups: healthy controls without diabetes or peripheral neuropathy 
(Ctrl, n=31, 19 men), patients with diabetes but no neuropathy (DM, n=22, 12 men) and 
patients with diabetes and moderate-severe peripheral neuropathy (DPN, n=14, 14 men). All 
participants were assessed to confirm they satisfied the inclusion criteria for each group. 
Exclusion criteria for participation in the study were vascular disease, unstable ischemic heart, 
neurological, rheumatic disease, cerebral injury, disorders of the vestibular system, 
musculoskeletal injury, recent surgery affecting gait, foot or lower limb amputation 
(amputation of the hallux; amputation of more than two lesser toes on one foot; amputation of 
part of/whole foot) and open foot ulcer. Information about duration and type of diabetes, 
smoking habits and use of current medication was obtained via questionnaire. The majority of 
the DM and the DPN patients reported taking insulin, cholesterol-lowering medication and 
diabetes medication, while from the whole sample (including controls) only 2 people reported 
smoking. Participant characteristics are displayed in Table 1. 
 
Assessment of peripheral neuropathy 
A clinical evaluation was undertaken to quantify neuropathy in diabetic patients and to confirm 
the absence of neuropathy in healthy controls. Peripheral neuropathy was assessed by using the 
modified Neuropathy Disability Score (mNDS) and the vibration perception threshold (VPT). 
The mNDS is a combined score taken from tests measuring the patient’s ability to detect 
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temperature, pain, vibration and the Achilles tendon reflex (10). The VPT was assessed by 
placing the probe of the biothesiometer on the apex of the hallux and increasing the level of 
vibration until detected by the participant. A random blood glucose test was performed in the 
Ctrl group to confirm the absence of diabetes and the above neuropathy tests conducted to 
confirm the absence of neuropathy in the Ctrl group resulting from any aetiology. 
 
Gait analysis 
Participants were asked to walk along a 10-metre walkway in the gait laboratory. Participants 
were instructed to walk the length of the walkway at a series of different walking speeds 
performed in a specific order (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s). Walking speed was controlled 
by measuring the velocity of a marker attached to the sacrum after each trial from the motion 
analysis data and providing immediate feedback for participants as to whether they needed to 
walk more quickly or more slowly on the next trial to achieve the required speed. Participant's 
starting position was altered by the experimenters to ensure a ‘clean’ (i.e., no overlap outside 
the force platform) foot-strike on one or two of the force platforms per walking trial without 
alteration to their natural gait. Walking trials were repeated until at least three ‘clean’ foot 
contacts with the force platforms were made per limb, per speed condition. Kinematics were 
collected at 100 Hz using a full-body modified Plug-In-Gait marker set with 54 markers and a 
10-camera Vicon motion capture system (Vicon, Oxford, UK) positioned around the 10-meter 
walkway. Kinetics were simultaneously collected at 1000 Hz from three force platforms 
(Kistler, Zurich, Switzerland) embedded into the middle of the walkway. Where possible 
markers were placed directly onto the skin; to minimise movement artefacts resulting from 
loose clothing all participants wore tight-fitting shorts and tops. All participants wore specialist 
diabetic shoes (MedSurg, Darco, Raisting, Germany) with a neutral foot-bed, ensuring the 
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diabetic patients walked with safe, appropriate footwear whilst minimising the effect of 
footwear by standardising across all participants. 
 
Oxygen uptake measurements and metabolic calculations 
Prior to testing, all participants completed walking familiarisation sessions for a minimum of 6 
minutes on the treadmill to become accustomed to the task of treadmill walking and enable a 
natural walking style to be achieved. Measurements of expired air were acquired whilst 
participants walked on a motor-driven treadmill (Woodway Ergo ELG 70, Weil am Rhein, 
Germany) set at six different walking velocities (0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 m/s). The 
treadmill was inclined by 1% from horizontal for the purpose of increasing the similarity of 
oxygen uptake demands with level ground walking as previously shown (34, 38). Participants 
wore a facemask, which passed expired air into an automated analyser (Cortex Metalyser 3B, 
Biophysik, Leipzig, Germany). The analyser, calibrated prior to each testing session, provided 
breath-by-breath data sent via telemetry to a computer. Oxygen consumption (VO2) was 
measured continuously using this online system. The net VO2 during walking was determined 
as: 
Net VO2 = gross VO2 - resting VO2× 
×resting VO2 was measured during quiet standing on the treadmill prior to walking. 
  
Net VO2 was expressed relative to body mass for all participants. The cost of walking was 
calculated using the mean rate of oxygen consumption for VO2 data collected between the 3rd 
and 4th minute of each stage. 
Net VO2 was converted to joules using an energetic equivalent and calculated using the 
specific respiratory exchange ratio (RER) value from each participant as (29): VO2 • (4.94 • 
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RER + 16.04). The CoW was calculated by dividing VO2 by the walking speed and 
multiplying this value for the energy equivalent. Using the RER and calculating the energetic 
equivalent in this way takes into account possible differences between groups due to the 
contribution of the anaerobic energy system. Nine participants (Ctrl=3, DM=1, DPN=5) were 
unable to walk for a sufficient period of time at 1.6 m/s to derive adequate VO2 measurements 
at this specific speed. 
 
Gait biomechanical analysis 
Temporal–spatial parameters (walking speed, stance time) were calculated from the gait 
analysis testing session described above using Visual 3D software (C-motion Inc., MD, USA), 
using the process of inverse dynamics to calculate joint powers. Power curves during stance 
were calculated to assess concentric (positive) periods of power during the stance phase to 
calculate concentric joint work done, defined as the positive power-time integral (14). 
Concentric joint work done was then subsequently normalised to body mass. Work done 
(ankle, knee, and hip) was calculated taking into account data from both legs, across at least 
three trials (data from at least six stance phases). 
 
Statistics 
A one-way analysis of variance (ANOVA) was performed for all variables to assess between 
group differences. If the ANOVA was significant, a Fisher’s least significant difference (LSD) 
post-hoc test was used to test for differences between the diabetes groups (DM and DPN) and 
the control group. All values presented are means and standard deviation. All statistical tests 
were performed on SPSS statistical package (SPSS v21, Chicago, Illinois) with significance set 
at p<0.05. 
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RESULTS 
 
Participant characteristics  
There were significant differences between the groups in age, body mass and BMI, which were 
significantly greater in the DPN group (Table 1, p<0.01).  
 
Neuropathy assessments  
As expected, the DPN group displayed significantly higher values for the VPT and the mNDS 
compared to the Ctrl group (Table 1). The VPT and mNDS for the DM group were not 
significantly different from the Ctrl, underlining that this diabetic patient group had no 
neuropathy (Table 1). 
 
Temporal–spatial gait parameters  
The DPN group displayed significantly longer single limb stance times and shorter step lengths 
in all given speeds compared to Ctrl group (Table 2). 
 
Total joint work during walking at different speeds 
Total concentric work showed a very consistent pattern across all speeds with the Ctrl group 
displaying the highest values, followed by lower values in the DM group and the lowest values 
observed in the DPN group (Fig. 1). Compared to the Ctrl group, significantly lower joint work 
was observed at all speeds for the DPN group and all but 1.4 m/s for the DM group.   
 
Ankle, knee and hip joint work during walking  
Ankle concentric joint work was lower for the DPN group compared to the Ctrl group, 
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reaching significance at gait velocities of 0.8; 1.2; 1.4 and 1.6 m/s (Fig. 1). Knee concentric 
joint work was significantly lower in the DPN group compared to Ctrl at gait velocities of 0.6; 
0.8; 1.0; 1.2 and 1.6 m/s. In the DM group, knee concentric joint work was significantly lower 
compared to Ctrl at the gait velocity of 0.6 m/s. Hip concentric joint work was lower for the 
DPN group compared to Ctrl reaching significance at velocities of 0.6; 0.8 and 1.6 m/s. 
 
Cost of walking at different speeds 
There were significant differences in the CoW between the groups across the matched speeds 
tested, with the general pattern of a higher CoW in the DPN group, followed by the DM group 
and the lowest CoW in the Ctrl group (Table 2; Fig. 2). Significant differences in the CoW 
were mainly found between the DPN and Ctrl groups (at 0.6; 0.8; 1.0; 1.2 and 1.6 m/s), with 
some significant differences also present between DM and Ctrl groups at the higher gait 
velocities (1.4 and 1.6 m/s). 
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DISCUSSION 
This study has shown for the first time that when walking speed is matched, patients with 
diabetic neuropathy have a higher CoW compared to controls (Fig. 2). Despite a higher CoW, 
patients with diabetic neuropathy showed significantly reduced concentric lower limb joint 
work compared to controls at these matched speeds. The finding of lower joint work in patients 
with diabetic neuropathy is surprising considering that under ‘normal’ conditions lower 
concentric work is clearly linked to a lower CoW (67, 57), but we suggest possible reasons for 
this below.  
The finding of a higher CoW in patients with diabetic neuropathy when walking speed was 
matched likely reflects energetic inefficiencies resulting from a number of physiological and 
biomechanical factors. Firstly, animal models of diabetes have shown that tendons are stiffer 
due to the effects of non-enzymatic glycation. In human diabetic patients, this likely applies to 
the long Achilles tendon, which plays a major role in energy saving during walking under 
‘normal’ circumstances (3). Stiffening of the Achilles tendon with diabetes and especially 
diabetic neuropathy (presumably due to longer exposure with poor glycaemic control), would 
reduce the extensibility of the tendon. Based upon the lower joint moments developed in 
patients with diabetic neuropathy during gait (46, 52, 56, 81), it would be expected that the 
force on the Achilles tendon would be lower compared to controls. The stiffer Achilles tendon 
of patients with diabetic neuropathy would be expected to elongate less compared to controls, 
storing less elastic energy and requiring more energy to be generated by the plantar flexor 
muscles (assuming similar hysteresis compared to controls), thereby contributing to a higher 
CoW in diabetes patients.  
Higher levels of muscle co-activation during walking have been reported in diabetic patients 
compared to controls (1, 32). Considering that locomotion should reflect a fine balance 
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between activation and de-activation of agonist and antagonist muscles during specific phases 
of the gait cycle, an increase in the level of muscle co-activation will increase metabolic energy 
cost and could therefore be another factor contributing to increase the CoW at a given speed in 
patients with DPN. Foot deformities are common in diabetic patients (29, 78) and even subtle 
changes in foot structure would alter the application of force to the ground during walking (43, 
51). Changes in the application of force to the ground during walking (and running) will alter 
the mechanical leverage around the ankle joint, i.e., the external moment arm. This has been 
shown both in humans and animals (7, 8, 9, 5, 41, 42, 68, 12) and therefore such changes may 
increase the CoW in patients with DPN. Another contributing factor to the higher CoW in the 
DPN group is the increased step frequency (the DPN group had a shorter step length for a 
given speed, therefore requiring a higher step frequency) and greater body mass compared to 
the DM and the Ctrl groups. These two factors (increased step frequency and greater body 
mass) would increase the internal work required for moving the lower limbs and may 
contribute to a higher CoW in people with diabetes and particularly those with DPN (54). 
A higher CoW was clearly evident in patients with diabetes (DM group) and particularly in 
those with diabetic neuropathy (DPN group) across the matched walking speeds. In this study 
we examined a range of different walking speeds (from 0.6 until 1.6 m/s) and observed that the 
differences in the CoW between groups were most evident at the lower gait velocities (0.6-1.2 
m/s; Fig. 2). At the higher walking speeds, the pattern changes slightly with the CoW still 
remaining higher in patients with diabetes and diabetic neuropathy compared to controls, but 
with the differences being less evident than at the slower walking speeds. This may be 
explained by patients with diabetic neuropathy moving closer towards their maximal oxygen 
uptake when walking at velocities of 1.4 m/s and above. It is well known that diabetes patients 
engage in less physical activity (48, 55, 72, 73) and are therefore likely less fit i.e., have a 
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lower maximal oxygen uptake compared to non-diabetic controls (40, 65, 66). It is also a 
possibility that diabetes patients might have reached the lactate threshold earlier than controls 
(i.e., at lower walking speeds), which could have influenced the VO2 kinetics and the time to 
reach a relatively constant VO2. Specifically, with heavy exercise above the lactate threshold 
the VO2 slow component (i.e., the gradual rise in VO2 with constant workload) may be more 
pronounced (77) and there is a risk that diabetes patients may have reached their lactate 
threshold earlier than controls, thereby influencing our estimate for the CoW differently 
between diabetes and control participants. Although we did not measure the lactate threshold or 
the maximal oxygen uptake in our participants, previous studies have shown that the lactate 
threshold occurs in other populations at a VO2 between 50 and 55 ml/kg/min, or at running 
speeds of between 3.75 and 4.73 m/s (64, 26, 83, 2). These VO2 values (50-55 ml/kg/min) and 
running speeds (3.75-4.73 m/s) are considerably higher compared to those measured in our 
study (VO2 values of up to 13 ml/kg/min and walking speeds of up to 1.6 m/s; Table 2), and 
despite these previous reports being in healthy populations, it may suggest that all participants 
in the present study were well below their lactate threshold. Future work could be conducted to 
compare the CoW between these groups at relative exercise intensities, taking into account 
individual lactate thresholds. 
The CoW data in the present study are comparable with a number of previous studies 
conducted in similar populations reporting values ranging between 1.1 and 5 J (kg m)-1 (76, 25, 
75, 35, 15, 36, 6, 16, 18, 20, 53, 59). In the DPN group the CoW showed a U-shaped 
relationship with walking speed as previously reported in other populations (53), but this 
relationship was not as clearly evident in the DM and Ctrl groups (Fig 2). All three groups 
showed the same consistent pattern of increasing net VO2 with increasing walking speed. 
Slight differences in the RER values between groups likely explain the lack of a consistent U-
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shaped relationship between the CoW and walking speed across all three groups. The DPN 
group displayed particularly high standard deviations for the CoW (Fig. 2) and VO2 data (Table 
2). This high within-group variance is a consistent characteristic reported in previous studies 
with DPN patients for other gait variables, but here we also highlight the within-group variance 
associated with VO2 and CoW parameters in DPN patients.  
Across the matched walking speeds in the present study, there was a consistent pattern of lower 
total concentric joint work being developed by the DM group and particularly the DPN group 
compared to controls (Fig. 1). A slower walking speed is a consistent finding of previous 
studies in diabetic patients (5, 52, 60, 28). Whilst most other studies have examined only self-
selected walking speed (45, 21), the present study is the first to examine a range of different 
functionally relevant matched walking speeds (between 0.6 and 1.6 m/s) in the diabetic patient 
population. Since lower limb joint work is known to be closely linked to the CoW, joint work 
was examined in the present study to provide insight to the mechanism(s) for group differences 
in the CoW. We found a consistent pattern of lower joint work in the DM group and 
particularly in the DPN group compared to the Ctrl group for the hip, knee and ankle joints 
across walking speeds (Fig. 1). Theoretically, the same lower limb joint work was associated 
with a higher CoW in diabetic patients and particularly in patients with DPN, which can be 
observed by projecting vertically from any point on the x-axis on Fig. 3.  
It was surprising that diabetic patients were actually able to match the same walking speed as 
controls despite generating significantly reduced lower limb joint work. This interesting aspect 
might be explained by a number of kinematic alterations to gait made by diabetic patients with 
implications for joint kinetics. This may represent an ‘altered gait strategy’ in people with 
diabetes to enable them to meet the task demands in the face of compromised musculoskeletal 
properties and already elevated CoW due to energetic inefficiencies. Diabetic patients display a 
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reduced lower limb range of motion during walking compared to controls. This is achieved at 
least in part via shorter steps taken by diabetic patients during walking (Table 2). It is known 
that DM and DPN patients are able to lower joint moments and walk with shorter steps and this 
translates to less flexed joints, which in general means that the moment arms of the ground 
reaction force are smaller compared to the situation with more flexed joints. Smaller moment 
arms will lower the joint moments and since joint work is derived from the product of joint 
moments and joint angular speed (joint power), this kinematic strategy likely contributes 
towards reducing the joint work done during walking. Concentric contractions are associated 
with a relatively high metabolic load, whereas in contrast, this is much lower for isometric and 
eccentric contractions (27, 23). Despite these strategies to lower the joint moments, patients 
with DPN have a higher CoW presumably due to metabolic inefficiencies discussed above. If 
patients with DPN did not employ these ‘altered gait strategies’ presumably the CoW would be 
even higher.  
There are some limitations in the present study that should be acknowledged. Firstly, several 
participants were not able not complete walking on the treadmill at the highest speed (1.6 m/s). 
Secondly, body mass was significantly different between groups, however, this should not 
affect the two main parameters of the CoW and joint work, since both parameters were 
normalised for body mass. Also, the higher body mass in patients with DPN is a well-known 
characteristic of this population described in the literature (45, 39, 37). Although only a mean 
of 10 years difference, patients in the DPN group were significantly older than controls (66 to 
56 years, respectively), which might be a confounding factor for some of the variables 
examined. We did not measure blood lactate to confirm that all participants were working 
below their lactate threshold. This is a consideration since the VO2 slow component is much 
more pronounced during exercise above the lactate threshold compared to below as discussed 
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above. Although the intensity of the exercise during walking in the present study was unlikely 
sufficient for participants to exceed their lactate threshold based on comparison with previous 
studies (64, 26, 83, 2), it remains a note of caution since it would affect our interpretation of the 
CoW data if there were between-group differences in the onset of the lactate threshold 
occurring within the range of walking speeds examined.    
We have shown that the CoW is higher in patients with diabetes and particularly in those with 
diabetic neuropathy compared to controls when walking speed is matched. This higher CoW is 
likely due to energetic inefficiencies in diabetic patients reflecting physiological and 
biomechanical characteristics and occurs despite the development of lower concentric joint 
work in patients with diabetes and diabetic neuropathy. 
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Figure 1. Lower limb ankle, knee, hip and total concentric joint work across walking speeds 
from 0.6 to 1.6 m/s for healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, 
n=22) and diabetic patients with moderate/severe neuropathy (DPN, n=14). Values are group 
means and SD, **denotes significantly (P<0.01) different from the control group. 
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Figure 2. The cost of walking (CoW) plotted across walking speeds from 0.6 to 1.6 m/s for 
healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic 
patients with moderate/severe neuropathy (DPN, n=14). Nine participants (Ctrl=3, DM=1, 
DPN=5) were unable to walk for long enough to calculate the CoW at 1.6 m/s. Values are 
group means and SD, **denotes significantly (P<0.01) different from the control group. 
 
Figure 3. Mean data for the cost of walking (CoW) plotted against total concentric work 
during walking at walking speeds from 0.6 to 1.6 m/s for healthy controls (Ctrl, n=31), diabetic 
patients with no neuropathy (DM, n=22) and diabetic patients with moderate/severe neuropathy 
(DPN, n=14). The curves were fitted with a cubic function to yield R2 values over 0.98. 
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Table 1. Participant characteristics and results from neuropathy assessments. 
Variable 
Group 
Ctrl DM DPN 
Age (yr) 56 (10) 51 (9)** 66 (14)** 
Body mass (kg) 76 (10) 80.5 (12) 91.5 (18)** 
Height (m) 1.72 (0.12) 1.71 (0.09) 1.73 (0.11) 
BMI (kg/m2) 26 (3) 28 (4) 31 (4)** 
NDS (Score/10) 1 (1) 2 (1) 7 (2)** 
VPT (Volts) 6.1 (3.4) 8.2 (3.4) 27.4 (9.1)** 
Diabetes duration (years) - 14 (12) 14 (11) 
Type 1 diabetes - 7 4 
Type 2 diabetes - 15 10 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic 
patients with moderate/severe neuropathy (DPN, n=14). Significant differences from the Ctrl 
group are denoted by *(P<0.05) or ** (P<0.01). BMI = body mass index, NDS = neuropathy 
disability score, VPT = vibration perception threshold. Values are means (standard deviations). 
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Table 2. Temporal-spatial gait parameters and net oxygen uptake.  
    Variable Group 
 Ctrl DM DPN 
0.6 m/s 
Actual speed (m/s) 
 
0.57 (0.24) 
 
0.59 (0.16) 
 
0.61(0.11) 
Step length (m) 
Single limb stance time (sec) 
0.59 (0.20) 
0.902 (0.20) 
0.57 (0.24) 
0.841(0.23) 
0.51 (0.09)** 
0.958 (0.05)** 
Net VO2 (ml/min kg) 3.81 (1.11) 3.05 (1.69) 4.93 (2.95)** 
RER 0.89 (0.05) 0.93 (0.08) 0.96 (0.09) 
0.8 m/s    
Actual speed (m/s) 0.82 (0.27) 0.78 (0.21) 0.77 (0.19) 
Step length (m) 
Single limb stance time (sec) 
0.63 (0.21) 
0.801 (0.15) 
0.57 (0.21) 
0.842 (0.21) 
0.53 (0.05)** 
0.960 (0.05)** 
Net VO2 (ml/min kg) 5.11 (0.89) 5.00 (1.55) 6.56 (2.94)** 
RER 0.86 (0.09) 0.87 (0.11) 0.97 (0.07) 
1.0 m/s 
Actual speed (m/s) 
 
1.02 (0.17) 
 
1.04 (0.28) 
 
0.97 (0.13) 
Step length (m) 
Single limb stance time (sec) 
0.69 (0.15) 
0.713 (0.13) 
0.67 (0.05) 
0.741 (0.05) 
0.64 (0.04)* 
0.884 (0.05)* 
Net VO2 (ml/min kg) 6.44 (1.08) 6.89 (1.32) 7.75 (3.29)** 
RER 0.84 (0.04) 0.91 (0.06) 0.93 (0.03) 
1.2 m/s    
Actual speed (m/s) 1.18 (0.16) 1.22 (0.15) 1.22 (0.23) 
Step length (m) 
Single limb stance time (sec) 
0.76 (0.11) 
0.579 (0.31) 
0.75 (0.17) 
0.617 (0.05) 
0.69 (0.07)* 
0.682 (0.06)* 
Net VO2 (ml/min kg) 7.46 (1.15) 7.89 (1.29) 8.62 (2.65)** 
RER 0.87 (0.08) 0.91 (0.04) 0.91 (0.07) 
1.4 m/s    
Actual speed (m/s) 1.45 (0.19) 1.44 (0.12) 1.46 (0.19) 
Step length (m) 
Single limb stance time (sec) 
0.79 (0.12) 
0.555 (0.15) 
0.77 (0.17) 
0.579 (0.21) 
0.71 (0.11)* 
0.621 (0.14)* 
Net VO2 (ml/min kg) 9.22 (1.69) 10.73 (0.80)** 9.87 (2.89) 
RER 0.90 (0.07) 0.89 (0.05) 0.93 (0.06) 
1.6 m/s    
Actual speed (m/s) 1.62 (0.27) 1.57 (0.17) 1.59 (0.12) 
Step length (m) 
Single limb stance time (sec) 
0.81 (0.11) 
0.499 (0.15) 
0.80 (0.04) 
0.498 (0.11) 
0.74 (0.02)* 
0.525 (0.01)* 
Net VO2 (ml/min kg) 10.97 (4.45) 12.84 (3.35)** 12.19 (4.99)** 
RER 0.89 (0.04) 0.90 (0.07) 0.98 (0.06) 
Healthy controls (Ctrl, n=31), diabetic patients with no neuropathy (DM, n=22) and diabetic 
patients with moderate/severe neuropathy (DPN, n=14). Significant differences from the Ctrl 
group are denoted by *(P<0.05) or **(P<0.01). Values are means (standard deviations). Gait 
parameters were collected on the laboratory walkway. 
